Insider Buying: enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Buys 2,750 Shares of Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion purchased 2,750 shares of the firm’s stock in a transaction on Wednesday, December 27th. The stock was bought at an average price of $7.17 per share, for a total transaction of $19,717.50. Following the purchase, the insider now owns 2,002,750 shares in the company, valued at approximately $14,359,717.50. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

enGene Trading Down 3.0 %

Shares of NASDAQ ENGN opened at $9.02 on Monday. enGene Holdings Inc. has a 1-year low of $4.42 and a 1-year high of $43.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. The business’s 50 day moving average is $6.71 and its two-hundred day moving average is $9.68. The stock has a market capitalization of $398.38 million, a P/E ratio of -5.24 and a beta of -0.69.

enGene (NASDAQ:ENGN) last released its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.05. As a group, research analysts expect that enGene Holdings Inc. will post -1.56 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ENGN shares. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 target price on shares of enGene in a report on Tuesday, September 24th. Morgan Stanley reaffirmed an “overweight” rating and set a $40.00 price objective on shares of enGene in a report on Wednesday, September 11th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $33.67.

Institutional Investors Weigh In On enGene

Several hedge funds and other institutional investors have recently made changes to their positions in ENGN. Altitude Crest Partners Inc. purchased a new position in shares of enGene during the 1st quarter worth about $2,039,000. SR One Capital Management LP bought a new stake in enGene in the second quarter worth about $4,715,000. Logos Global Management LP boosted its position in shares of enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares during the period. Finally, Janus Henderson Group PLC bought a new position in shares of enGene during the first quarter valued at approximately $17,095,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.